Amylmetacresol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Amylmetacresol: From Throat Infection Relief (Lozenge) to Cauda Equina Syndrome
One-Sentence Summary
Amylmetacresol is a topical antiseptic used in throat lozenges and is marketed in Singapore as a single-ingredient lozenge product. The TxGNN model predicts it may be effective for cauda equina syndrome, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model prediction only, with no supporting studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration record (the product is a throat lozenge) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Amylmetacresol is known as a locally acting antiseptic in throat lozenges, with antibacterial and antiviral activity in the oropharynx. Some related lozenge compounds show weak local anaesthetic-like activity, possibly through sodium channel blockade.
No mechanistic link to cauda equina syndrome has been established. The drug is not used systemically, and cauda equina syndrome is a compressive neurological condition that is managed surgically. The high TxGNN score appears to reflect graph-based association rather than biological or clinical rationale.
Other top-ranked predictions are similarly unsupported: obsolete neurogenic bladder (likely a graph-proximity effect with cauda equina syndrome), irritable bowel syndrome, and several eye conditions (ciliary body disease, panuveitis, iris disease, infectious anterior uveitis, uveitis, ciliary body cancer and benign ciliary body neoplasm). All are L5, with no trials or publications. Infectious anterior uveitis has only a theoretical antimicrobial rationale, with no data on eye delivery or tolerability.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08806P | STREPSILS MAX PLUS LOZENGES | Lozenge | Not stated in the record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials or publications, no plausible mechanism, and no route of administration that could reach the target condition. The drug is a locally acting lozenge antiseptic.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), required before any safety screening
- Mechanism of action data (for example, from DrugBank)
- Any preclinical or clinical evidence linking amylmetacresol to the predicted conditions
- An assessment of route compatibility, since a topical oropharyngeal product is unlikely to be suitable for neurological, bowel or ocular targets
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.